$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000156459020007970 Filed on March 02, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Gross Profit	$0.00	$0.00	$0.00
YoY Change			-100.0%
Gross Profit Margin
Selling, General & Admin	$21.97M	$19.75M	$13.97M
YoY Change	72.92%	57.37%	30.07%
% of Gross Profit
Research & Development	$16.59M	$20.09M	$9.481M
YoY Change	70.48%	75.15%	-0.97%
% of Gross Profit
Depreciation & Amortization	$100.0K	$110.0K	$100.0K
YoY Change	0.0%	57.14%	0.0%
% of Gross Profit
Operating Expenses	$38.56M	$39.84M	$23.45M
YoY Change	71.89%	65.88%	15.44%
Operating Profit	-$38.56M	-$39.84M	-$23.45M
YoY Change	71.89%	65.88%	11.21%
Interest Expense	$810.0K	$1.010M	$1.260M
YoY Change	-19.8%	83.64%	125.0%
% of Operating Profit
Other Income/Expense, Net	-$40.00K	-$140.0K	-$60.00K
YoY Change	100.0%	16.67%
Pretax Income	-$37.79M	-$38.97M	-$22.25M
YoY Change	76.26%	65.2%	8.38%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$37.79M	-$38.97M	-$22.25M
YoY Change	76.24%	64.33%	8.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.786M	-$1.856M	-$1.064M
COMMON SHARES
Basic Shares Outstanding	21.15M	20.98M	20.90M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$119.1M	$147.1M	$158.2M
YoY Change	-51.72%	45.19%	44.47%
Cash & Equivalents	$27.69M	$49.69M	$66.15M
Short-Term Investments	$92.60M	$97.39M	$92.05M
Other Short-Term Assets	$2.800M	$1.500M	$1.700M
YoY Change	75.0%	50.0%	-10.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$121.9M	$148.6M	$159.9M
YoY Change	-50.91%	45.37%	43.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$991.0K	$977.0K	$893.0K
YoY Change	6.67%	3.06%	-10.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$40.10M	$48.60M	$63.50M
YoY Change
Other Assets	$500.0K	$264.0K	$2.423M
YoY Change	-81.99%	-16.72%	2323.0%
Total Long-Term Assets	$45.00M	$53.75M	$66.88M
YoY Change	1097.76%	3984.65%	5979.73%
TOTAL ASSETS
Total Short-Term Assets	$121.9M	$148.6M	$159.9M
Total Long-Term Assets	$45.00M	$53.75M	$66.88M
Total Assets	$166.9M	$202.4M	$226.8M
YoY Change	-33.78%	95.43%	101.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.152M	$4.694M	$2.638M
YoY Change	144.24%	9.88%	-58.13%
Accrued Expenses	$10.10M	$14.80M	$11.50M
YoY Change	17.44%	202.04%	325.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.20M	$19.48M	$14.09M
YoY Change	38.17%	44.69%	56.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.300M	$2.600M	$1.700M
YoY Change	4.55%
Total Long-Term Liabilities	$2.300M	$2.600M	$1.749M
YoY Change	5.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.20M	$19.48M	$14.09M
Total Long-Term Liabilities	$2.300M	$2.600M	$1.749M
Total Liabilities	$16.48M	$22.09M	$15.84M
YoY Change	32.21%	64.03%	75.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$265.8M	-$228.0M	-$189.0M
YoY Change	84.18%	85.52%
Common Stock	$416.0M	$408.0M	$57.00K
YoY Change	742673.21%	91.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$150.5M	$180.3M	$210.9M
YoY Change
Total Liabilities & Shareholders Equity	$166.9M	$202.4M	$226.8M
YoY Change	-33.77%	95.43%	101.38%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$37.79M	-$38.97M	-$22.25M
YoY Change	76.24%	64.33%	8.37%
Depreciation, Depletion And Amortization	$100.0K	$110.0K	$100.0K
YoY Change	0.0%	57.14%	0.0%
Cash From Operating Activities	-$35.64M	-$26.00M	-$12.53M
YoY Change	98.7%	152.92%	35.02%
INVESTING ACTIVITIES
Capital Expenditures	$96.00K	-$200.0K	-$50.00K
YoY Change	118.18%	900.0%	-85.29%
Acquisitions
YoY Change
Other Investing Activities	$13.12M	$9.490M	-$12.61M
YoY Change
Cash From Investing Activities	$13.03M	$9.300M	-$12.66M
YoY Change	-29702.27%	-46600.0%	3623.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	90.00K	240.0K	1.130M
YoY Change	-99.94%	-89.09%	-5750.0%
NET CHANGE
Cash From Operating Activities	-35.64M	-26.00M	-12.53M
Cash From Investing Activities	13.03M	9.300M	-12.66M
Cash From Financing Activities	90.00K	240.0K	1.130M
Net Change In Cash	-22.52M	-16.46M	-24.06M
YoY Change	-115.47%	103.21%	149.59%
FREE CASH FLOW
Cash From Operating Activities	-$35.64M	-$26.00M	-$12.53M
Capital Expenditures	$96.00K	-$200.0K	-$50.00K
Free Cash Flow	-$35.73M	-$25.80M	-$12.48M
YoY Change	98.75%	151.46%	39.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2019Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1460746
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Alexander Park
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
CY2019	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
CY2019Q2	dei	Entity Public Float EntityPublicFloat	695300000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49688000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	97389000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	523000
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	253000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19482000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2604000
CY2019Q4	us-gaap	Liabilities Liabilities	22086000
CY2018Q4	us-gaap	Liabilities Liabilities	13465000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21026184
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21026184
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16214883
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16214883
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	57000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	44000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	407986000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	212921000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228017000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122871000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	276000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	180302000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	90094000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	202388000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103559000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	672000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	148634000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	102243000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	977000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	948000
CY2019Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000
CY2018Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	51000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3735000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1034000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11186000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6711000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1585000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	48555000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	264000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	317000
CY2019Q4	us-gaap	Assets Assets	202388000
CY2018Q4	us-gaap	Assets Assets	103559000
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8540000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4925000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13465000
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-38079
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
CY2019	dei	City Area Code CityAreaCode	646
CY2019	dei	Local Phone Number LocalPhoneNumber	768-9780
CY2019	dei	Trading Symbol TradingSymbol	URGN
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21154965
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101318000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-75657000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-20000000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-105146000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	276000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-104870000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75657000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.12
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-75657000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-20000000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1128000
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8158000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	1803000
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	600000
CY2019	us-gaap	Gross Profit GrossProfit	18000
CY2018	us-gaap	Gross Profit GrossProfit	-675000
CY2017	us-gaap	Gross Profit GrossProfit	7558000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36934000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18697000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8811000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.14
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20528727
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15754193
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9716790
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	16307000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	404000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6300000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-105146000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-75532000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19981000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	125000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-75657000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20000000
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.80
CY2017	urgn	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	4732000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	68515000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2401000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30642000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	90094000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3664000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29967000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	276000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-105146000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	180302000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-105146000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-75657000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-20000000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	296000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	417000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	207000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	572000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	29967000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	30642000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	6300000
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	168000
CY2018	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-100000
CY2019	urgn	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	1028000
CY2019	urgn	Operating Lease Liability Adjustments OperatingLeaseLiabilityAdjustments	910000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-316000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	211000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-83000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	394000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-318000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	562000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2928000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4205000
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2534000
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-650000
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	650000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1786000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2975000
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1263000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-71017000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37334000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9568000
CY2018	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-35901000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	197686000
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	36001000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	52590000
CY2019	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	172000
CY2018	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	54000
CY2017	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	5000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	325000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36277000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3664000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2401000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	404000
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	382000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	76000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	161662000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64235000
CY2018	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	215000
CY2017	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	42000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	66421000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61585000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-51360000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	64374000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15740000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37197000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21457000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50211000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	101571000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37197000
CY2019	urgn	Noncash Issuance Cost NoncashIssuanceCost	188000
CY2018	urgn	Noncash Issuance Cost NoncashIssuanceCost	102000
CY2017	urgn	Noncash Issuance Cost NoncashIssuanceCost	202000
CY2019	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	1741000
CY2017	urgn	Noncash Exercise Of Warrants To Preferred Shares NoncashExerciseOfWarrantsToPreferredShares	4732000
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1-BUSINESS AND NATURE OF OPERATIONS</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nature of Operations</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>April<span style="letter-spacing:0.4pt;"> </span>20<span style="letter-spacing:-0.1pt;">0</span>4. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Inc.,<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>subsidiary<span style="letter-spacing:0.8pt;"> </span>of UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.,<span style="letter-spacing:0.45pt;"> </span>was<span style="letter-spacing:0.35pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Del<span style="letter-spacing:-0.1pt;">a</span>ware<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2015<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>began<span style="letter-spacing:0.5pt;"> </span>operati<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>February<span style="letter-spacing:0.75pt;"> </span>2016. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.<span style="letter-spacing:0.4pt;"> and UroGen Pharma Inc.</span><span style="letter-spacing:0.35pt;"> </span>(together<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>“Company”)<span style="letter-spacing:0.95pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases. </span><span style="letter-spacing:0.45pt;"> </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company’s product candidates may never achieve commercialization and it will continue to incur losses for the foreseeable future. Therefore, in order to fund the Company’s research and development expenses, general and administrative expenses and capital expenditures until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.</p>
CY2019	urgn	Entity Incorporation Date Of Incorporation Month And Year EntityIncorporationDateOfIncorporationMonthAndYear	2004-04
CY2019	urgn	Operations Commenced Date Month And Year OperationsCommencedDateMonthAndYear	2016-02
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	162942000
CY2019Q4	urgn	Debt Securities Available For Sale Unrealized Gain Position DebtSecuritiesAvailableForSaleUnrealizedGainPosition	300000
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	17900000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228000000.0
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122900000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	162942000
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	89965000
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000
CY2017	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	22000000.0
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>preparation<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>conformity<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.35pt;"> </span>U.S.<span style="letter-spacing:0.4pt;"> </span>GAAP<span style="letter-spacing:0.5pt;"> </span>requires<span style="letter-spacing:0.65pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>make<span style="letter-spacing:0.45pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>affect the<span style="letter-spacing:0.05pt;"> </span>reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities,<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>disclosure<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>cont<span style="letter-spacing:-0.1pt;">i</span>ngent<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financ<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>the reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenues<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>expenses<span style="letter-spacing:0.8pt;"> </span>duri<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>reporting<span style="letter-spacing:0.7pt;"> </span>period.<span style="letter-spacing:0.55pt;"> </span>Actual<span style="letter-spacing:0.5pt;"> </span>results<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>differ<span style="letter-spacing:0.45pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>those<span style="letter-spacing:0.45pt;"> </span>estimates.<span style="letter-spacing:0.8pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>to these<span style="letter-spacing:0.45pt;"> </span>consolidated<span style="letter-spacing:1pt;"> </span>financi<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:0.65pt;"> </span>statements,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>most<span style="letter-spacing:0.4pt;"> </span>significant<span style="letter-spacing:0.8pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>relate<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>fair<span style="letter-spacing:0.3pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>compensat<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>timing<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue<span style="letter-spacing:0.65pt;"> </span>recognition.</p>
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	17
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11725000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<span style="color:#000000;">’</span>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">’</span>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p>
CY2018Q4	urgn	Operating Leases Future Minimum Payments Due In Six Years And Thereafter OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter	58000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3989000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000
CY2019	urgn	Schedule Of Accrued Expenses And Other Current Liabilities ScheduleOfAccruedExpensesAndOtherCurrentLiabilities	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consist of the following as of December 31, 2019 and 2018, respectively (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,694</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,272</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,644</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">780</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued general and administrative expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,029</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">682</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,786</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,186</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,540</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div>
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4694000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4272000
CY2019Q4	urgn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	399000
CY2018Q4	urgn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	673000
CY2019Q4	urgn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2644000
CY2018Q4	urgn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	780000
CY2019Q4	urgn	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	2767000
CY2018Q4	urgn	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	1029000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	682000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1786000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11186000
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8540000
CY2019	urgn	Number Of Performance Obligation NumberOfPerformanceObligation	2
CY2019Q4	urgn	Upfront Fee Allocated To License Component UpfrontFeeAllocatedToLicenseComponent	17500000
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2749000
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	629000
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	761000
CY2019Q4	urgn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	800000
CY2019Q4	urgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	896000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	762000
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	114386000
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	89965000
CY2019Q4	urgn	Available For Sale Securities Debt Maturities After One Through Three Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue	48556000
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	168000
CY2019	urgn	Interest Income Expenses On Cash Cash Equivalents And Marketable Securities InterestIncomeExpensesOnCashCashEquivalentsAndMarketableSecurities	4616000
CY2018	urgn	Interest Income Expenses On Cash Cash Equivalents And Marketable Securities InterestIncomeExpensesOnCashCashEquivalentsAndMarketableSecurities	1872000
CY2017	urgn	Interest Income Expenses On Cash Cash Equivalents And Marketable Securities InterestIncomeExpensesOnCashCashEquivalentsAndMarketableSecurities	125000
CY2018	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-100000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-284000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-124000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000
CY2019	urgn	Interest And Other Income Expenses Net InterestAndOtherIncomeExpensesNet	4332000
CY2018	urgn	Interest And Other Income Expenses Net InterestAndOtherIncomeExpensesNet	1648000
CY2017	urgn	Interest And Other Income Expenses Net InterestAndOtherIncomeExpensesNet	-31000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-105146000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-75657000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-20000000
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	825000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-105146000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75657000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20825000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20528727
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15754193
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9716790
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.12
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.80
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.14
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	162666000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	280000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1975000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1695000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	998000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	747000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	977000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	948000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000
CY2019	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	UroGen Pharma Ltd. signed an addendum to its November 2014 lease agreement for the Company’s principal executive offices located in Israel, in order to increase the office space rented and to extend the rent period until September 2019, with an option to extend the lease for an additional period of three years. In 2019, the option was exercised, and the lease period was extended until September 2022.
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2019	urgn	Lessee Operating Lease Extended Lease Expiration Date Month And Year LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear	2022-09
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1243000
CY2019	us-gaap	Sublease Income SubleaseIncome	19000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	105000
CY2019	us-gaap	Lease Cost LeaseCost	1329000
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3022000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3735000
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2429000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2604000
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	929000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1585000
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1192000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1741000
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M28D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0554
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1758000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1269000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1101000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	348000
CY2019Q4	urgn	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	58000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4534000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	345000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4189000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	598000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5000
CY2019Q4	urgn	Deferred Tax Liabilities Depreciable Fixed Assets DeferredTaxLiabilitiesDepreciableFixedAssets	90000
CY2018Q4	urgn	Deferred Tax Liabilities Depreciable Fixed Assets DeferredTaxLiabilitiesDepreciableFixedAssets	93000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	62000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	84000
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	24000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	50593000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28249000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1136000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1251000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	676000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	567000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	301000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21000000.0
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21000000.0
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16200000
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16200000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	955732
CY2019	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	33.21
CY2019	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	47.57
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1195000
CY2018	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	38.64
CY2018	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	59.23
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	589600
CY2017	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	1.78
CY2017	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	39.26
CY2019	urgn	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted	27600000
CY2018	urgn	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted	40300000
CY2017	urgn	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted	10900000
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	30800000
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M19D
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9600
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14200000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	31600000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	21400000
CY2019Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2871335
CY2019Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1574999
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29967000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30642000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6300000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.24
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33817000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16943000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5844000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	61000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	46000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4591000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3891000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2887000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6543000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4769000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	897000
CY2019Q4	urgn	Deferred Tax Assets Issuance Costs DeferredTaxAssetsIssuanceCosts	2063000
CY2018Q4	urgn	Deferred Tax Assets Issuance Costs DeferredTaxAssetsIssuanceCosts	1367000
CY2017Q4	urgn	Deferred Tax Assets Issuance Costs DeferredTaxAssetsIssuanceCosts	1261000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28249000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11725000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4158000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-22344000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-16524000
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-7567000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	50593000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28249000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11725000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	2600000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	600000
CY2019	urgn	Federal And State Net Operating Losses Expiration Year FederalAndStateNetOperatingLossesExpirationYear	2036
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	151900000
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	72100000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-23716000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-75657000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.14
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.28
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.46
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.80
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	22433000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	23771000
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	23453000
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	39839000
CY2019	us-gaap	Operating Expenses OperatingExpenses	109496000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22433000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23753000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23453000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-39839000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-109478000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-21444000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-22477000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-22252000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-38973000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-105146000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.06
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.86
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.12
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	481000
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	364000
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	283000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1128000
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	13691000
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	18480000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	20317000
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	24017000
CY2018	us-gaap	Operating Expenses OperatingExpenses	76505000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13640000
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18434000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21089000
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-24017000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-77180000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-13382000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-18026000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-20533000

Files In Submission

Name	View Source	Status
0001564590-20-007970-index-headers.html	Edgar Link	pending
0001564590-20-007970-index.html	Edgar Link	pending
0001564590-20-007970.txt	Edgar Link	pending
0001564590-20-007970-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g004x2mjzalt000001.jpg	Edgar Link	pending
g004x2mjzalt000002.jpg	Edgar Link	pending
g004x2mjzalt000003.jpg	Edgar Link	pending
g004x2mjzalt000004.jpg	Edgar Link	pending
g004x2mjzalt000005.jpg	Edgar Link	pending
g2lou4bvvoer000001.jpg	Edgar Link	pending
ggkz0rn2wzls000001.jpg	Edgar Link	pending
ggkz0rn2wzls000002.jpg	Edgar Link	pending
ggkz0rn2wzls000003.jpg	Edgar Link	pending
ggkz0rn2wzls000004.jpg	Edgar Link	pending
ggkz0rn2wzls000005.jpg	Edgar Link	pending
ggkz0rn2wzls000006.jpg	Edgar Link	pending
ggkz0rn2wzls000007.jpg	Edgar Link	pending
ggkz0rn2wzls000008.jpg	Edgar Link	pending
ggkz0rn2wzls000009.jpg	Edgar Link	pending
ggkz0rn2wzls000010.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-10k_20191231.htm	Edgar Link	pending
urgn-10k_20191231_htm.xml	Edgar Link	completed
urgn-20191231.xsd	Edgar Link	pending
urgn-20191231_cal.xml	Edgar Link	unprocessable
urgn-20191231_def.xml	Edgar Link	unprocessable
urgn-20191231_lab.xml	Edgar Link	unprocessable
urgn-20191231_pre.xml	Edgar Link	unprocessable
urgn-ex1014_260.htm	Edgar Link	pending
urgn-ex1015_414.htm	Edgar Link	pending
urgn-ex211_411.htm	Edgar Link	pending
urgn-ex231_8.htm	Edgar Link	pending
urgn-ex311_7.htm	Edgar Link	pending
urgn-ex312_12.htm	Edgar Link	pending
urgn-ex321_15.htm	Edgar Link	pending
urgn-ex42_412.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2020 Q1 Form 10-K Financial Statement

#000156459020007970 Filed on March 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2020 Q1 Form 10-K Financial Statement

#000156459020007970 Filed on March 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn